Conference Coverage

CANVAS program analysis: Canagliflozin benefits patients with T2DM and poor kidney function

Publish date: July 6, 2018

 

REPORTING FROM ADA 2018

SOURCE: de Zeeuw D et al. ADA 2018, Abstract 258-OR.

Pages

Recommended Reading

Intensive treatment for T2D pays off in the long run
MDedge Family Medicine
Alirocumab’s benefit greater in diabetes patients: ODYSSEY Outcomes
MDedge Family Medicine
Pancreas volume studies may offer insight into T1DM
MDedge Family Medicine
Blood pressure targets: How low should you go (and for whom)?
MDedge Family Medicine
Diabetes in the elderly: Matching meds to needs
MDedge Family Medicine
Dietary recommendations for patients with diabetes
MDedge Family Medicine
High-bleeding-risk AF patients cut stroke risk with Amplatzer Amulet
MDedge Family Medicine
Diabetes risk may rise with work hours
MDedge Family Medicine
Study questions canagliflozin amputation risk, but concerns remain
MDedge Family Medicine
High risk of low glucose? Hospital alerts promise a crucial heads-up
MDedge Family Medicine

Related Articles